WALTHAM,
Mass., July 1, 2024 /PRNewswire/ -- Q32 Bio Inc.
(Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company
focused on developing biologic therapeutics to restore immune
homeostasis, today announced that the company is joining the
broad-market Russell 3000® Index at the conclusion of
the 2024 Russell Indexes annual reconstitution, effective upon the
U.S. market opening today, July 1,
2024.
"We are pleased to be included in the Russell 3000®
Index as we approach our anticipated milestones, progress our
pipeline for severe autoimmune and inflammatory diseases, and
continue to expand our shareholder base," said Lee Kalowski, President and Chief Financial
Officer of Q32 Bio.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. The annual Russell U.S. Indexes
reconstitution captures the 4,000 largest U.S. stocks as of
April 30, 2024, ranking them by total
market capitalization. Membership in the U.S. all-cap Russell
3000® Index, which remains in place for one year, means
automatic inclusion in the large-cap Russell 1000® Index
or small-cap Russell 2000® Index as well as the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings, and style attributes.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing
biologic therapeutics targeting potent regulators of the innate and
adaptive immune systems to re-balance immunity in autoimmune and
inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7
/ TSLP receptor pathways and complement system, address immune
dysregulation to help patients take back control of their
lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914),
is a fully human anti-IL-7Rα antibody that re-regulates adaptive
immune function for the treatment of autoimmune diseases. It is
being evaluated in two Phase 2 trials for the treatment of atopic
dermatitis and alopecia areata. The IL-7 and TSLP pathways have
been genetically and biologically implicated in driving several T
cell-mediated pathological processes in numerous autoimmune
diseases. Q32 Bio's program for innate immunity, ADX-097, is based
on a novel platform enabling tissue-targeted regulation of the
complement system without long-term systemic blockade – a key
differentiator versus current complement therapeutics. Q32 Bio has
completed a first-in-human, Phase 1 ascending dose clinical study
of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our
investors and the public using our company
website www.Q32Bio.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference
call transcripts and webcast transcripts, as well as on X (formerly
Twitter) and LinkedIn. The information that we post on our website
or on X or LinkedIn could be deemed to be material information. As
a result, we encourage investors, the media and others interested
to review the information that we post there on a regular basis.
The contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Forward-Looking Statements
This communication contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995, as amended, relating to our business, operations and
financial condition, including but not limited to current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, our clinical results and related
timing, including statements regarding expectations regarding
anticipated milestones, among others.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as "may," "will," "should,"
"would," "expect," "anticipate," "plan," "likely," "believe,"
"estimate," "project," "intend," and other similar expressions
among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: interim, topline and preliminary
data may change as more patient data become available, and are
subject to audit and verification procedures that could result in
material changes in the final data; data generated from our
preclinical and clinical studies may not meet our expectations; our
product candidates may not provided the intended therapeutic
benefits; our product candidates may cause serious adverse side
effects; the ability to integrate our business with our merger
partner successfully and to achieve anticipated synergies; the
possibility that other anticipated benefits of the merger will not
be realized, including without limitation, anticipated revenues,
expenses, earnings and other financial results, and growth and
expansion of our operations, and the anticipated tax treatment of
the merger; our ability to retain, attract and hire key personnel;
potential adverse reactions or changes to relationships with
employees, suppliers or other parties resulting from the completion
of the merger; potential business uncertainty, including changes to
existing business relationships that could affect our financial
performance; the need for additional funding, which may not be
available; failure to identify additional product candidates and
develop or commercialize marketable products; the early stage of
our development efforts; potential unforeseen events during
clinical trials could cause delays or other adverse consequences;
risks relating to the regulatory approval process; the inability to
maintain our collaborations, or the failure of these
collaborations; our reliance on third parties, including for the
manufacture of materials for our research programs, preclinical and
clinical studies; failure to obtain U.S. or international marketing
approval; ongoing regulatory obligations; effects of significant
competition; unfavorable pricing regulations, third-party
reimbursement practices or healthcare reform initiatives; product
liability lawsuits; securities class action litigation; the impact
of global pandemics and general economic conditions on our business
and operations, including the our preclinical studies and clinical
trials; the possibility of system failures or security breaches;
risks relating to intellectual property; significant costs incurred
as a result of operating as a public company; and such other
factors as are set forth in Q32 Bio's periodic public filings with
the SEC, including but not limited to those described under the
heading "Risk Factors" in our Form 10-Q filed with the Securities
and Exchange Commission on May 9,
2024 and any subsequent filings made with the Securities and
Exchange Commission. Except as required by applicable law, we
undertake no obligation to revise or update any forward-looking
statement, or to make any other forward-looking statements, whether
as a result of new information, future events or otherwise.
Contacts:
Investors: Brendan
Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/q32-bio-joins-russell-3000-index-302186365.html
SOURCE Q32 Bio